News & Updates
Filter by Specialty:
Tenecteplase at 4.5–24 hours without thrombectomy feasible for ischaemic stroke
The use of tenecteplase in the extended time window of 4.5–24 hours improves functional outcomes in patients with ischaemic stroke when endovascular thrombectomy (EVT) is not immediately available, findings from the phase III TRACE-III* trial suggest.
Tenecteplase at 4.5–24 hours without thrombectomy feasible for ischaemic stroke
11 Sep 2024
Hydroxychloroquine protects SLE patients against CV events
Among patients with systemic lupus erythematosus (SLE), those who use of hydroxychloroquine are less likely to experience cardiovascular events, as reported in a study.
Hydroxychloroquine protects SLE patients against CV events
11 Sep 2024
Antidepressant nonresponders may benefit from rTMS
Repetitive transcranial magnetic stimulation (rTMS) demonstrates greater reduction in depressive symptoms than switching of antidepressant medications in patients with moderately treatment-resistant depression, reveals a study.
Antidepressant nonresponders may benefit from rTMS
10 Sep 2024
Ustekinumab biosimilar SB17 boasts similar efficacy, safety in psoriasis
SB17, a proposed ustekinumab (UST) biosimilar, demonstrates comparable efficacy, safety, and pharmacokinetics (PK) to the reference drug, as well as lower immunogenicity up to week 28, among individuals suffering from moderate-to-severe psoriasis, according to a study.
